|

Apalutamide Clinical Trials

19 actively recruiting trials across 11 locations

▲ +1 trial since August 2026

Also known as: ARN 509, ARN-509, ARN509, ERLEADA®, Erleada +2 more

Pipeline

Phase 1: 2Phase 2: 9Phase 3: 6Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • Janssen Research & Development, LLC2
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • Sun Pharmaceutical Industries Limited1
  • Monte Rosa Therapeutics, Inc1

Indications

  • Cancer19
  • Castration-resistant Prostate Cancer3
  • Metastatic Hormone-sensitive Prostate Cancer2
  • Biochemically Recurrent Prostate Carcinoma2
  • Stage IIIB Prostate Cancer AJCC V82

Other5 trials

Los Angeles, California3 trials

Anchorage, Alaska2 trials

Dothan, Alabama1 trial

Gilbert, Arizona1 trial

Phoenix, Arizona1 trial

Tucson, Arizona1 trial

Duarte, California1 trial

Aurora, Colorado1 trial

Phase 1

Sarasota, Florida1 trial

Cleveland, Ohio1 trial

Houston, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.